Relevium Medical
YC S22 · Active · Platform injectable gel based therapeutic for osteoarthritis
Competitors
| Company | Category | Status | Program |
|---|---|---|---|
 Velorum TherapeuticsShared: drug discovery, therapeutics, healthcareActiveOther | Other | Active | YCW24 |
 Origami Therapeutics, Inc.Shared: drug discovery, therapeutics, progressiveActiveOther | Other | Active | YCW22 |
 Eris BiotechShared: drug discovery, therapeutics, developingActiveOther | Other | Active | YCW24 |
 Gerostate AlphaShared: therapeutics, disease, developingInactiveOther | Other | Inactive | YCS18 |
 Encepheal TherapeuticsShared: drug discovery, therapeutics, opioidInactiveOther | Other | Inactive | YCS19 |
Adjacent
| Company | Category | Status | Program |
|---|---|---|---|
 Valink TherapeuticsShared: drug discovery, therapeuticsActiveOther | Other | Active | YCW21 |
 ParcelBioShared: drug discovery, therapeutics, diseaseActiveOther | Other | Active | YCW24 |
 SafeBeatShared: therapeutics, medical devicesActiveAI | AI | Active | YCS21 |
 Phoenix KineticsShared: knee osteoarthritis, pain relief, patientNot statedOther | Other | Not stated | Plug and Play |
 AlixiaShared: drug discovery, therapeuticsActiveOther | Other | Active | YCW22 |
Also from S22
All of S22
About Relevium Medical
Relevium Medical is developing an injectable gel for knee osteoarthritis. Approximately half the population will be diagnosed with this pain and progressive disease. Right now, patients have to undergo not only repeat injections to control their pain, but also have to take strong oral medications. Because the disease is progressive and only gets worse over time, many patients end up on highly addictive, high-dose opioids. To date, we have secured $3.7 million in non dilutive funding and completed preclinical testing. We demonstrated that our drug is safe, selectively blocks nerves that transmit pain, and provides pain relief that lasts four times as long. Insurance currently pays $770 per six-monthly treatment for knee osteoarthritis. With 5 million patients in the US, this represents a $7.7 Bn market opportunity. This platform biotherapeutic can also be used to treat other joints affects by osteoarthritis such as the hip and ankle, where the same problems exist in treatment care.
- YC batch
- S22 · Summer 2022
- Status, per YC
- Active
- Category
- Other
- Team size
- 5
- Location
- Galway, County Galway, Ireland
- Checked
- 1h ago
YC tags: Medical Devices, Healthcare, Therapeutics, Drug discovery
Relevium Medical: questions
Which YC batch was Relevium Medical in?
Relevium Medical was in Y Combinator's Summer 2022 batch (S22).
Is Relevium Medical still active?
Y Combinator lists Relevium Medical as active.
Where is Relevium Medical based?
Relevium Medical lists Galway, County Galway, Ireland as its location on YC's directory.
Sources: each program's public company list, read twice a week. Not affiliated with Y Combinator or any other program. Logos via logo.dev; trademarks belong to their owners.